Objective. The overall aim of this study was to estimate the total costs for patients with RA, AS and psoriatic arthritis (PsA) treated with DMARDs. Specific aims were to compare the costs across diagnoses and over time.
Introduction
Advances in the treatment of inflammatory rheumatic diseases have improved the health-related quality of life of patients with inflammatory rheumatic joint diseases. DMARDs are the main treatment for these patients [1, 2] . The cost of biologic DMARDs, which is substantially higher than that of conventional, synthetic DMARDs [35] , is of concern to payers. Based on systematic literature reviews, recent European League Against Rheumatism recommendations for the management of RA highlighted that the treating rheumatologist should consider both direct and indirect costs (productivity losses) of treatment [2, 5] . Worker productivity is usually subdivided into absenteeism (time off work) and presenteeism (time at work with reduced level of productivity) [6] . Both concepts can be applied as a cost indicator for interventional studies [7] . The conceptualization and measurement of absenteeism and presenteeism are not without difficulties and differ across studies [6] . In our study, productivity loss was limited to absenteeism, i.e. health-related absence from work [7] . RA is associated with increased sick leave [810] , and recent studies from Sweden have investigated the effects of treatment with biologic DMARDs on sick leave [11, 12] and workforce participation [12, 13] among RA patients. Augustsson et al. [13] found that treatment with TNF inhibitors was associated with increases in workforce participation over time for patients up to 55 years of age. Olofsson et al.
[11] reported a decline in sick leave during the first 6 months on TNF inhibitor treatment, which persisted in the subsequent 6 months. Neovius et al. [12] found a deterioration of work ability during 4 years before treatment initiation. The deterioration was followed by a flat work ability level for all patients after biologic DMARD initiation and an increasing work ability for patients with <5 years of RA duration, analysing days on sick leave and disability pension in combination. A multinational study of patients with long-standing, severe RA (disease duration of >12 years) reported reduced productivity loss over a period of 144 weeks after initiation of adalimumab, but the changes were not statistically significant [14] .
Assessing the costs of treatment is an integral part of a cost-effectiveness analysis [15, 16] . Cost analyses for RA have been performed in Japan [17] , Turkey [18] , Colombia [19] , France [20] , Hungary [21] , The Netherlands [22] and Sweden [23] ; for AS in Tunisia [24] and the UK [25] ; and for PsA in Hong Kong [26] . Few comparisons of costs, however, have been made across different types of inflammatory joint diseases. Another gap in the current knowledge lies in the scarcity of recent real-life cost data for RA, AS and PsA. We took advantage of a systematic collection of data focusing on resource utilization in patients starting therapy with synthetic and biologic DMARDs [1] and assessed direct and indirect costs during a 2-year period.
The aim of this study was to compare actual treatment costs and productivity losses in patients with RA, AS and PsA and to assess the costs over time. We adopted a societal perspective to capture all cost consequences of the three diseases.
Methods

Patient population
The primary data source was the Norwegian DMARD register study (NOR-DMARD) [1] . Patients with inflammatory arthropathies are included when they start treatment with synthetic and/or biologic DMARDs. Patients from five rheumatology departments in hospitals with a total catchment area of 1.4 million inhabitants have been included since 2000 and followed longitudinally [1, 27] . The choice of DMARD regimen is made by the treating rheumatologists and is based on clinical judgement and existing recommendations. Assessments are performed at baseline, after 3, 6 and 12 months and then yearly up to change of DMARD treatment or treatment termination [1] . A new baseline registration is performed every time a patient starts a DMARD regimen. This means that each patient can be registered twice or more if the treatment is changed. In February 2010, NOR-DMARD comprised 9919 treatment courses in a total of 6518 individual patients.
The study was approved by the Norwegian Data Inspectorate and the Regional Ethics Committee of South-Eastern Norway. Patients gave written informed consent before participation.
We excluded patients who discontinued the regimen during the first 24 months to be able to compare costs over time, and included patients on their first DMARD regimen with RA (n = 1152), AS (n = 186) and PsA (n = 374) with, in total, 1712 treatment courses (Fig. 1) . The main characteristics of included patients are shown in Table 1 . As expected, the diagnostic groups differed in terms of demographic variables such as age, gender, disease duration and employment status, and with regard to the proportion that started treatment with biologic vs synthetic DMARDs.
The instruments in the data collection A research nurse or physician collected demographic information and details about the disease, such as laboratory findings and joint counts at each visit. Changes in health and working status and DMARD dosages were registered by the nurse or physician. The patients were asked about their use of health care during the period from previous to current visit. The research nurse registered the use of visits to general practitioners (GPs), private rheumatologists, physical therapists and outpatient clinics, and the number of imaging examinations, in-hospital stays and stays in rehabilitation units. The patients filled out a written questionnaire and the patient-reported outcomes included among others visual analogue scales for joint pain, fatigue and global disease activity as well as the Modified Health Assessment Questionnaire, EQ-5D and SF- 36 .
Further details about the data collection and imputations in case of missing data are described in supplementary data (available at Rheumatology Online).
Study design and analyses
We estimated treatment costs for each of the 6-month periods in the first year of the first DMARD regimen and, then, for the second year. The analyses included patients who completed 2 years of follow-up on their first DMARD regimen and had complete cost assessments after imputations (supplementary Table S1 , available as supplementary data at Rheumatology Online). We calculated mean costs for all included cost components and compared 2-year costs across diagnoses with the stratification for synthetic and biologic DMARDs. We also compared costs (direct, indirect and total) between the first and last 6 months (defined as the second-year cost divided by 2).
Cost data in NOR-DMARD
The NOR-DMARD database includes information on diagnosis, age, sex, type of medication, disease duration, education and employment status as well as several outcome measures for disease activity and quality of life. In addition, NOR-DMARD includes data on the patients' use of health care. The patients' use of synthetic and biologic www.rheumatology.oxfordjournals.org DMARDs, including infusions (dates and doses), glucocorticoids (GCs) and concomitant medications are systematically recorded (supplementary Table S2 , available as supplementary data at Rheumatology Online).
Direct costs
Direct costs included pharmaceuticals, visits to GPs, private rheumatologists, physical therapists and outpatient clinics, imaging examinations, in-hospital stays and stays in rehabilitation units ( Table 2 ). The patients were asked about their use of health care during the period before the visit (since last visit).
The drug prices were taken from the Norwegian Medicines Agency's price database in 2010 regarding conventional DMARDs, GCs, anti-inflammatory agents and analgesics or from the Physician's Desk Book from 2004 for older drugs [28] . Norway has free pricing for over-the-counter (OTC) drugs, and we used the prices of a local pharmacy for OTC analgesics. The prices of biologics were taken from the Norwegian Drug Procurement Cooperation (http://www.lisnorway.no). This organization purchases expensive drugs for the hospitals based on tender. All drug prices were exclusive of value-added tax.
Indirect costs
The terms indirect costs and productivity loss are used interchangeably in our study. Productivity loss is limited to work absenteeism and defined as productivity loss due to health-related absence from work [7] . At inclusion, each patient was asked about work status and the status was recorded in six categories: (i) retired due to age; (ii) on disability pension or rehabilitation benefits; (iii) on sick leave; (iv) fully employed; (v) working part time; (vi) other (students, unemployed, etc.). Changes in work status over time were recorded at the follow-up assessments by a research nurse or physician. Patients in categories (i) and (vi) were excluded from the productivity loss calculations, as they were assumed to have no productivity losses.
Cost calculations
For each patient, all drugs used between assessments were summarized. The use of DMARDs was calculated by multiplying doses expressed in milligram by frequency (daily, weekly or monthly). Infusions of biologic DMARDs were registered by date and dose and these were summarized for each patient and period. Concomitant medications, registered by start and stop dates, were added
FIG. 1 Flow chart of included patients.
for each patient and period. For concomitant medications, the defined daily dose (DDD) from WHO Collaborating Centre for Drug Statistics Methodology was used. If the patient used the medication as a regular regimen, the DDD was counted as one and if the patient used the medication as needed, the DDD was multiplied by 0.25.
Other cost variables were summarized for each patient and period (Table 2) . In all cost variables, patient co-payments were included. A travel cost was added to all visits to hospitals, GPs, physical therapists, etc., except for imaging examinations, which were assumed to take place at the same time as some other visit. . Patients who were unable to work, including patients on disability pension, rehabilitation and sick leave, the median income plus the social cost of labour (40% of the income) was added as a productivity loss. For patients who were able to work part time, this productivity cost was reduced in proportion to the time worked. We adopted the human capital approach, assuming that the productivity loss persisted throughout the analysed time period [15] . Additionally, we calculated the indirect and total costs with the friction cost method, assuming a friction period of 5 months. Human capital and friction cost data are presented in parallel in Tables 3 and 4 . If not otherwise mentioned, the results presented in the 'Results' section are calculated with the human capital approach.
Finally, all pharmaceutical, other health-care and productivity costs were summarized and means for all costs were calculated by diagnosis and 6-month period. All costs were expressed in 2011 euros (E1.00 = NOK 7.808.15).
Missing values and statistics
We replaced missing dose frequencies by the mode frequency for that particular DMARD, with the exception of some drugs given as infusions, for which we used irregular schemes. Missing data on dosages of DMARDs were replaced by multiple imputations using multivariate normal regression models (Stata MP11, College Station, TX, USA). We performed imputations separately for each DMARD. Missing values for other cost variables, such as hospital stays and GP visits, were also replaced by multivariate normal regression models. For further information, see supplementary data (available at Rheumatology Online).
CIs of the mean total 2-year costs were calculated by 10 000 bootstrapped estimates since the distributions of total costs were not normal. Differences in total costs across diagnoses were tested by KruskalWallis equality-of-populations rank test and CIs for median differences were calculated by the HodgesLehmann's estimator. Differences in costs between first and last 6-month periods were tested by paired t-tests because these differences were normally distributed. P < 0.05 were considered significant.
Results
The total 2-year costs across diagnoses were similar when we compared patients on synthetic DMARD treatment (Table 3) . For biologic DMARD treatment, RA patients had the highest mean and median total costs (mean E121 900), followed by AS (mean E115 300) and PsA (mean E111 200), but the differences were not statistically significant (Table 3) , either using the human capital or the friction cost approach.
The largest cost component across all diagnoses and treatment types was productivity loss, followed by the cost of DMARDs for biologic treatment and the cost of in-hospital care for synthetic treatment (Table 3) . When the friction cost was used, DMARDs were the largest cost component for biologic treatment, followed by productivity loss.
The total costs of the first 6-month period on synthetic and biologic DMARD therapy is shown in Table 4 . In the last 6-month period, the total costs were 9% lower in RA, 11% lower in PsA and 18% lower in AS patients treated with synthetic DMARDs. Cost reductions in patients treated with biologic DMARDs were 9, 17 and 13% in the respective diagnoses compared with the first 6-month period. The changes in total costs from the first to the last 6-month periods were significant in all diagnoses for both synthetic and biologic treatment (P < 0.05). Changes in total costs for synthetic DMARDs were significant for RA and PsA but not for AS. Both the direct and indirect costs declined, but not all combinations of diagnoses and therapy declined significantly. When the friction cost was used, the indirect costs declined significantly in all combinations of diagnoses and therapy, as expected using this approach (Table 4 ). The reduction in cost due to productivity gain was 75% in RA, 77% in PsA and 93% in AS patients after 2 years of synthetic DMARD treatment. For patients on biologic DMARDs, the corresponding reductions were relatively smaller since the drug costs made major contributions to the total cost denominator (reductions were 25, 56 and 18% for RA, PsA and AS, respectively).
Discussion
The results of this study indicate that initiation of biologic DMARD treatment in patients with RA, AS and PsA entailed considerable costs, but the total treatment costs declined over time. Indirect costs due to productivity losses declined similarly across diagnoses and treatment types (Table 4 ). There were no significant differences in the total 2-year costs between the diagnoses.
RA patients on biologic DMARD had higher total 2-year costs than patients with AS and PsA (Table 3) . For synthetic DMARD treatment, there were small differences between the patient groups. This observation is consistent with a previous Dutch review [31, 32] . The higher costs in our study compared with those reported in the Dutch review can partly be explained by a focus on different time periods. The review, which encompassed studies from 1988 to 2007, may not have fully captured the fundamental change in treatment strategies that have occurred over the past decade [2] . Additionally, the costs in the review were expressed in 2006 euros, while we used 2010 prices. Norway currently has the second highest health-care costs globally, which may also contribute to the difference.
A German study by Huscher et al. [33] compared the costs of RA, AS, PsA and also SLE. As with the German study, our study was register based, but in addition we could provide patient level data on medication.
TABLE 3
Direct and indirect cost components in euros over 2 years according to the diagnosis and synthetic or biologic DMARD The numbers in parenthesis are percentages of total mean costs, calculated by the human capital method.
www.rheumatology.oxfordjournals.org Huscher et al. concluded that RA generated a higher total cost (E15 637 over 12 months) than AS (E13 513). This result is consistent with the results in our study, although we found no significant differences between diagnoses. Further, the German study found that PsA (E11 075) was the least costly disease. PsA was also the least costly among the three diseases for patients treated with biologics in our study. However, Huscher et al. used 2002 data, and compared with those results we found two times greater costs for RA and three times greater for AS and PsA. Several studies report 1-year assessments [25, 26, 33] , while some have a longer time perspective [17, 22, 23] . We adopted a 2-year perspective and analysed costs per 6-month period because our data include half-year-level details in the first year on DMARD treatment.
The decline in total costs over the 2-year period may have different explanations. This observation may reflect a regression to the mean [34] , because patients might be in a particularly poor health state when DMARD treatment is considered and initiated. Thus the reductions in treatment and productivity loss over time could be explained by an improved health state that would have occurred irrespective of DMARD treatment.
A second explanation may be that the accuracy of the registration of use of health care may decline over time. The first two intervals between registrations are 3 months long followed by a 6-month interval and thereafter a 12-month interval. However, we attempted to counteract such bias by replacing missing values through multiple imputations as described in supplementary data (available at Rheumatology Online) [35] . Additionally, the registration in NOR-DMARD is performed by a research nurse or physician, which can improve the quality of the data. Thirdly, DMARD treatment might yield a real reduction in the use of health care and work absenteeism. Our data are in accordance with this hypothesis, but should be interpreted with caution in this non-randomized study.
Fourth, we included only patients who completed 2 years of treatment, thus they had tolerated the treatment and had sufficient response to continue treatment. This selection is made with the aim of estimating costs over 2 years, but the selection might have contributed to negative bias in the non-drug costs. However, it is of importance to see how the costs develop over time for patients with sufficient treatment response. In randomized controlled studies, the time perspective is normally shorter and one of the strengths with register-based studies is that costs and effects can be followed over time.
The indirect costs of biologic treatment in patients with RA declined significantly in the first 2 years of treatment with the friction cost method and in absolute numbers with the human capital approach, consistent with previous findings indicating that TNF inhibitors have a positive effect on work productivity [36] . In a recent study, Olofsson et al.
[11] reported a decline in sick leave in RA patients during the first 6 months of treatment with TNF inhibitors, and this reduction persisted during the subsequent 6 months. Our study adds to that finding by showing that a decline in work absenteeism might be maintained throughout 2 years for RA patients on biologic treatment. Augustsson et al. [13] report an increase in participation in the workforce for RA patients (up to 55 years of age) who were treated with TNF inhibitors over a 5-year period. They included patients who dropped out during the study, only 56 of 594 remained on treatment for 5 years, which may create bias in the comparisons. Our study indicates that RA patients of working age who remain on the same biologic therapy can expect a reduction in productivity loss over a 2-year period. The indirect costs for patients treated with biologic DMARDs decline for all diagnoses over 2 years. These findings are valuable information for decision makers with a societal perspective.
Even though this study was based on register data, it has several limitations both with respect to utilization of drugs and services, and with respect to unit costs. The costs of in-hospital and outpatient care including infusion of i.v. drugs may not be accurate due to lack of direct cost data. We used estimates from the Norwegian DRG-based hospital financing system, which may not have correct cost estimates [29] . The results may not be entirely representative of Norwegian patients, although there is little reason to assume that patients in the included areas are different from those of the rest of the country.
Another limitation lies in the use of self-reporting for work absenteeism. However, patients' self-reporting was registered by a research nurse or physician, and this may have improved data quality. A better approach would have been to link the NOR-DMARD data to the social security data, as recently done with Swedish register data [11, 12, 37] .
The human capital and the friction cost approaches were used to value productivity losses. The human capital method implies that productivity losses are accounted for during the whole period of work absenteeism. The friction cost approach assumes that absent workers will be replaced by others after a friction period of searching and learning. In this analysis, we chose to use a friction period of 5 months. This latter method results in lower indirect costs, but the choice between methods is controversial [15, 38, 39] . Assuming a steady state of employment, the friction cost method may be optimal, but in Norway where there is a lack of labour, the assumption of a steady state of employment may not be met and the human capital approach could be an alternative. Since choice of treatment type was based on clinicians' discretion, it is inevitable that patients on biologics were different from those on synthetic DMARDs (Table 1) . Differences in costs between treatment types may therefore be in part explained by differences in severity, disease duration and other medical factors.
Treatment cost studies quickly become outdated because of changes in treatment recommendations and clinical practice. However, we had access to clinical data from the continuously updated NOR-DMARD register. We conclude that inflammatory rheumatic joint diseases www.rheumatology.oxfordjournals.org are costly to society with no clear differences in total costs across diagnoses. Biologic DMARD treatment entails considerable drug costs, but the total disease costs seem to decline during the first 2 years of treatment for patients with RA as well as AS and PsA.
Rheumatology key messages
. The largest cost component across inflammatory rheumatic diseases depends on the methodology for evaluating productivity loss. . Total costs decline over time for patients treated with DMARDs in RA, AS and PsA.
